Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vaccinex (VCNX) Reports Q4 Revenues Beat Estimates
March 13, 2019 7:24 AM EDTVaccinex (NASDAQ: VCNX) reported Q4 revenue for the quarter came in at $194 thousand versus the consensus estimate of $100 thousand.
The fourth quarter caps a year of significant progress at Vaccinex, during which we transitioned to a publicly-traded company and continued to advance pepinemab in a number of serious and difficult to treat medical conditions, including cancer and... More
